Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Enarodustat
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ONNARO (enarodustat) is a new generation of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), was approved for the treatment of non-dialysis-dependent patients with anemia caused by chronic kidney disease.
Product Name : Onnaro
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2023
Lead Product(s) : Enarodustat
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JK07
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Carlyle
Deal Size : $260.0 million
Deal Type : Acquisition
Carlyle to Acquire 5% Stake in Salubris, a Leading Biopharmaceutical Company in China
Details : Salubris has developed a comprehensive innovative pipeline in the treatment of chronic diseases, including JK07, an innovative biologic drug treating heart failure which has filed for clinical trial approvals in both China and the United States.
Product Name : JK07
Product Type : Protein
Upfront Cash : Undisclosed
January 09, 2020
Lead Product(s) : JK07
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Carlyle
Deal Size : $260.0 million
Deal Type : Acquisition
Reset All
